Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis<sup>1</sup>-Reference-Cited by-同舟云学术

Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis¹

Published:2022-07-21 Issue:1 Volume:11 Page:1790-1805
ISSN:2222-1751
Container-title:Emerging Microbes & Infections
language:en
Short-container-title:Emerging Microbes & Infections

Author:

Shen Hongbo¹,Yang Enzhuo¹²,Guo Ming³,Yang Rui¹,Huang Guixian¹,Peng Ying¹,Sha Wei¹,Wang Feifei⁴,Shen Ling²

Affiliation:

1. Shanghai Clinical Research Center for Infectious Disease (tuberculosis), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Institute for Advanced Study, Tongji University School of Medicine, Shanghai, People’s Republic of China

2. Department of Microbiology & Immunology and Center for Primate Biomedical Research, University of Illinois College of Medicine, Chicago, IL, USA

3. State Key Laboratory of Virology, Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, People’s Republic of China

4. Department of Medical Microbiology and Parasitology, Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China

Funder

Shanghai Science and Technology Committee

Chinese National Major Projects

National Natural Science Foundation of China

Fundamental Research Funds for the Central Universities

Publisher

Informa UK Limited

Subject

Virology,Infectious Diseases,Drug Discovery,General Medicine,Immunology,Microbiology,Parasitology,Epidemiology

Link

https://www.tandfonline.com/doi/pdf/10.1080/22221751.2022.2095930

Reference38 articles.